{"nctId":"NCT00718315","briefTitle":"A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.","startDateStruct":{"date":"2009-04"},"conditions":["Non-Small Cell Lung Cancer"],"count":201,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]","Drug: fusidic acid [Verutex]"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]","Drug: erythromycin [Eritex]"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]","Drug: Fisiogel"]}],"interventions":[{"name":"erlotinib [Tarceva]","otherNames":[]},{"name":"fusidic acid [Verutex]","otherNames":[]},{"name":"erythromycin [Eritex]","otherNames":[]},{"name":"Fisiogel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* locally advanced or metastatic non-small cell lung cancer (stage IIIB/IV);\n* eligible to start treatment with Tarceva, or receiving Tarceva for \\<=5 days.\n\nExclusion Criteria:\n\n* presence of skin rash or other signs of skin toxicity;\n* treatment with any systemic or intranasal antibiotic within 7 days before randomization;\n* treatment with other topical formulation within 14 days before randomization;\n* other anticancer therapy in addition to Tarceva.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Develop Skin Rash","description":"Skin rash was assessed by the investigator and dermatologists (the latter ones only through pictures) and scored according to (National cancer Institute -Common Terminology Criteria for Adverse Events ) NCI-CTCAE ( version 3 (line \"Rash/desquamation\" - short name \"rash\").","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"69.2","spread":null},{"groupId":"OG002","value":"73.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Skin Rash Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"25.0","spread":null},{"groupId":"OG002","value":"18.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null},{"groupId":"OG001","value":"18.3","spread":null},{"groupId":"OG002","value":"43.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"56.7","spread":null},{"groupId":"OG002","value":"35.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Appearance of Skin Rash","description":"Time to occurence of skin rash was calculated as the number of days from Day 0 until the first appearance of skin rash as defined by NCI-CTCAE","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"15.0","spread":null},{"groupId":"OG002","value":"15.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Erythema","description":"Erythema is defined as redness of the skin or mucous membranes, caused by hyperemia of superficial capillaries","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"56.7","spread":null},{"groupId":"OG002","value":"43.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pruritus","description":"Pruritus is defined as intense localized itching","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"47.6","spread":null},{"groupId":"OG002","value":"29.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pain","description":"Pain is defined as an unpleasant feeling often caused by intense or damaging stimuli","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":null},{"groupId":"OG001","value":"25.4","spread":null},{"groupId":"OG002","value":"13.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Erythema Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null},{"groupId":"OG001","value":"39.7","spread":null},{"groupId":"OG002","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"36.5","spread":null},{"groupId":"OG002","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"22.2","spread":null},{"groupId":"OG002","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pruritus Stratified by Severity Grade","description":"The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":null},{"groupId":"OG001","value":"52.4","spread":null},{"groupId":"OG002","value":"70.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"31.7","spread":null},{"groupId":"OG002","value":"24.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"14.3","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pain Stratified by Severity Grade","description":"The severity of pain was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null},{"groupId":"OG001","value":"73.0","spread":null},{"groupId":"OG002","value":"85.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"22.2","spread":null},{"groupId":"OG002","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":67},"commonTop":["Diarrhea","Fatigue (asthenia, lethargy, malaise)","Anorexia","Dyspnea (shortness of breath)","Pulmonary/upper respiratory"]}}}